Kiora Stock Story

All Stories . Hype . 
Vlad Skutelnik .  Story
KPRX
 Stock
  

USD 0.16  0.02  11.11%   

By Vlad Skutelnik
Macroaxis Story
In general, we focus on analyzing Kiora (NASDAQ:KPRX) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kiora Pharmaceuticals daily price indicators and compare them against related drivers. Today's article will break down Kiora Pharmaceuticals. I will address few reasons this entity was abused by investors due to the current market volatility.
Published over a month ago
View all stories for Kiora Pharmaceuticals | View All Stories

Is Kiora Pharmaceuticals (NASDAQ:KPRX) losing trust from investors?

The company secures a Beta (Market Risk) of 0.4946, which conveys possible diversification benefits within a given portfolio. Let's try to break down what Kiora's beta means in this case. As returns on the market increase, Kiora Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Kiora Pharmaceuticals will be expected to be smaller as well. Even though it is essential to pay attention to Kiora Pharmaceuticals price patterns, it is always good to be careful when utilizing equity historical price patterns. Our philosophy towards estimating any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Kiora Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate its performance. Kiora Pharmaceuticals has an expected return of -0.15%. Please be advised to verify Kiora Pharmaceuticals standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Kiora Pharmaceuticals performance from the past will be repeated at some point in the near future.
The successful prediction of Kiora Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Kiora Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Kiora Pharmaceuticals based on Kiora Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Kiora Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Kiora Pharmaceuticals's related companies.

Watch out for price decline

Please consider monitoring Kiora Pharmaceuticals on a daily basis if you are holding a position in it. Kiora Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Kiora Pharmaceuticals stock to be traded above the $1 level to remain listed. If Kiora Pharmaceuticals stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

Use Technical Analysis to project Kiora expected Price

Kiora Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Overlap Analysis
View
Forecast Models
View
Price Shifting
View
Volatility Indicators
View
Value Movement
View
A focus of Kiora Pharmaceuticals technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Kiora Pharmaceuticals trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How does Kiora utilize its cash?

To perform a cash flow analysis of Kiora Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Kiora Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Kiora Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Kiora Pharmaceuticals Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Kiora Pharmaceuticals reported Net Cash Flow from Operations of (10.68 Million) in 2021

Payment of 108 shares by Romano Sarah of Kiora Pharmaceuticals subject to Rule 16b-3

Legal trades by Kiora Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Kiora insider trading alert for payment of common stock by Romano Sarah, Chief Financial Officer, on 11th of February 2022. This event was filed by Kiora Pharmaceuticals Inc with SEC on 2022-02-11. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

The company reported the previous year's revenue of 12.06 K. Net Loss for the year was (16.39 M) with loss before overhead, payroll, taxes, and interest of (5.35 M).

Deferred Revenue Breakdown

Kiora Pharmaceuticals Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Deferred Revenue is likely to outpace its year average in 2022. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Kiora Pharmaceuticals Deferred Revenue is fairly stable at the moment as compared to the past year. Kiora Pharmaceuticals reported Deferred Revenue of 3.09 Million in 2021
2010
2016
2017
2018
2021
2022
20101.91 Million
20164.22 Million
201712.31 Million
20182.69 Million
20213.09 Million
20224.68 Million

Analysis of Kiora Pharmaceuticals

The standard deviation is down to 6.92 as of today.
As of the 9th of July, Kiora Pharmaceuticals secures the risk adjusted performance of (0.07), and Mean Deviation of 4.42. Kiora Pharmaceuticals technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Kiora Pharmaceuticals, which can be compared to its peers in the industry. Please verify Kiora Pharmaceuticals standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Kiora Pharmaceuticals is priced some-what accurately, providing market reflects its recent price of 0.46 per share. As Kiora Pharmaceuticals is a penny stock we also strongly advise to check its total risk alpha numbers.

Our Takeaway on Kiora Pharmaceuticals Investment

While some firms in the biotechnology industry are either recovering or due for a correction, Kiora Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. While some investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Kiora Pharmaceuticals.

Editorial Staff

Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Kiora Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2022 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY